ArticleCancer medicine2026
Up to Four-Year Outcomes of Single-Fraction Stereotactic Radiosurgery for Small Brain Metastases: A Competing-Risk Analysis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSingle-fraction stereotactic radiosurgery (SRS) is recommended for small brain metastases (< 2 cm). However, long-term outcomes accounting for competing risks-particularly death, which precludes observation of local treatment failure (LTF)-remain limited.
methodsWe retrospectively analyzed cumulative incidences of LTF, defined as tumor regrowth within the planning target volume, following 18 Gy single-fraction SRS (July 2014-December 2021) in patients with brain metastases. Patients with prior radiotherapy or surgery to the index lesion were excluded. Cumulative incidences of LTF, death without prior LTF, overall survival (OS), and progression-free survival (PFS) were estimated. Outcomes were compared between radioresistant (melanoma, sarcoma, renal cell carcinoma) and radiosensitive tumors. Subdistribution hazard ratios (SDHRs) and cause-specific hazard ratios (CSHRs) identified risk factors for each endpoint.
resultsSeventy-two patients (median age 62 years, IQR 55-68) with median tumor volume 0.3 cc (IQR 0.2-0.7) were followed for a median of 57.2 months (IQR 49.3-85.4). Thirty-three tumors were radioresistant and 39 radiosensitive. At 36 months, cumulative LTF was 62% (95% CI, 42%-77%) versus 31% (95% CI, 17%-46%) in radioresistant versus radiosensitive tumors (p = 0.011), whereas death without prior LTF was 19% (95% CI, 7%-34%) versus 46% (95% CI, 30%-61%) (p = 0.003). OS was 42% (95% CI, 28%-63%) and 36% (95% CI, 24%-55%), and PFS was 19% (95% CI, 9%-40%) and 23% (95% CI, 13%-41%), respectively. Radioresistant histology was associated with higher LTF hazard (CSHR 3.19; SDHR 3.91) and lower hazards of death without prior LTF (CSHR 0.37; SDHR 0.24), with no significant effect on OS or PFS. The 36-month cumulative incidence of radiation necrosis was 10% (95% CI, 4%-18%).
conclusionLocal control after 18 Gy SRS is poor in radioresistant brain metastases. Higher LTF incidence is amplified by lower competing mortality, highlighting the interplay between tumor biology and survival. These findings support competing risk-based analyses and consideration of alternative dose-escalation for high-risk tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.